Whereas BRAF mutated melanomas have efficient targeted treatment options with BRAF-inhibitors (vemurafenib, dabrafenib and encorafenib) in combination with MEK-inhibitors (cobimetinib, trametinib and binimetinib), NRAS was thought to be an “undruggable” target due to missing FDA-approved targeted therapies available [10,11,12,13,14,15,16]. This evidence concerns the gene BRAF and melanoma.